SCHEMBL3429688

SCHEMBL3429688

O=C(Nc1ccc2c(c1)OC(F)(F)O2)c1nn(Cc2ccc(C(=O)N3CCOCC3)cc2)c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.48
FLT3 P36888 1/20 0.47
PTGER4 P35408 6/20 0.43
CNR1 P21554 1/20 0.43
LMNA P02545 3/20 0.43
RAB9A P51151 3/20 0.43
TP53 P04637 2/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
NPC1 O15118 3/20 0.42
USP2 O75604 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
FAAH O00519 1/20 0.41
KCNH2 Q12809 1/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3429976 0.95 FLT3 (0.47) MAPK1FLT3PTGER4CNR1LMNA
SCHEMBL12996463 0.92 FLT3 (0.44) MAPK1FLT3PTGER4CNR1LMNA
SCHEMBL3431403 0.89 RAB9A (0.56) MAPK1FLT3LMNARAB9ATP53
SCHEMBL3760296 0.88 NPC1 (0.57) MAPK1FLT3PTGER4LMNARAB9A
SCHEMBL3431802 0.84 PTGER4 (0.46) FLT3PTGER4CNR1RAB9APOLB
SCHEMBL3428148 0.83 FLT3 (0.55) FLT3PTGER4CNR1LMNAALDH1A1
SCHEMBL3430489 0.82 PTGER4 (0.47) PTGER4CNR1RAB9APOLBNPC1
SCHEMBL3428309 0.81 PTGER4 (0.59) FLT3PTGER4LMNATP53MAPT
SCHEMBL3428968 0.81 FLT3 (0.52) FLT3PTGER4CNR1LMNARAB9A
SCHEMBL3428348 0.81 IDH1 (0.44) PTGER4CNR1RAB9APOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 MAPK1 2158/4885FLT3 4692/4885PTGER4 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.